OOIR: Observatory of International Research

Papers

(The H4-Index of Critical Reviews in Oncology Hematology is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting	373
Stereotactic body radiation therapy versus conventional external beam radiation therapy for painful bone metastases: A systematic review and meta-analysis of randomized trials	242
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm	155
Letter to the Editor regarding the article “A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs app	119
Comparative efficacy of first-line therapies for PD-L1-negative advanced NSCLC: A network meta-analysis with reconstructed survival curves	114
From immunohistochemistry to machine learning-based patient stratification by tumour proliferation characteristics in head and neck cancer	87
Beyond the blood-brain barrier: Intranasal vaccines in cancer immunotherapy	87
Direct and indirect effects on child neurocognitive development when maternal cancer is diagnosed during pregnancy: What do we know so far?	86
Advancing tumor vaccines: Overcoming TME challenges, delivery strategies, and biomaterial-based vaccine for enhanced immunotherapy	85
Real-world analysis of primary central nervous system diffuse large B-cell lymphoma	81
A systematic review and meta-analysis of blood-based biomarkers in anal squamous cell cancer treated with chemoradiotherapy	68
Harnessing tumor metabolism during cancer treatment: A narrative review of emerging dietary approaches	66
A non-invasive miRNA-based approach in early diagnosis and therapeutics of oral cancer	66
Novel bioengineered drugs with immunotherapies for malignant pleural effusion: Remodulate tumor immune microenvironment and activate immune system	65
When immunity backfires: Meta-analysis on sarcoidosis reactivation in cancer patients treated with immune checkpoint inhibitors	64
Navigating management of localized prostate cancer in the geriatric population	61
Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice	59
Dysregulation of systemic immunity in colorectal cancer and its clinical applications as biomarkers and therapeutics	59
Cytokine-based NK cell engineering for cancer immunotherapy	58
Salivary phosphate: A promising non-invasive biomarker for oral and systemic disease screening	53
Unveiling the Role of JAK2/STAT3 signaling in chemoresistance of gynecological cancers: From mechanisms to therapeutic implications	52
The role of cGAS-STING in remodeling the tumor immune microenvironment induced by radiotherapy	51
Skin barrier dysfunction in cutaneous T-cell lymphoma: From pathogenic mechanism of barrier damage to treatment	51
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II	48
Beyond monospecificity: The modular revolution of bispecific immunotherapeutics	48

Development of treatment strategies for advanced HER2-positive gastric cancer: Insights from clinical trials	47
Systemic immune-inflammation index as a predictor of survival in non-small cell lung cancer patients undergoing immune checkpoint inhibition: A systematic review and meta-analysis	46
Microbiome and lung cancer: carcinogenic mechanisms, early cancer diagnosis, and promising microbial therapies	45
Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): ‘Where the streets have no name’	45
Novel insight into the Warburg effect: Sweet temptation	44
Targeted doublet therapy with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer: A systematic review and meta-analysis	44
Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models	43
Current status of locally advanced rectal cancer therapy and future prospects	43
Efficacy of PD-1/PD-L1 immunotherapy on brain metastatic non-small-cell lung cancer and treatment-related adverse events: A systematic review	43
The cytokines in tumor microenvironment: from cancer initiation-elongation-progression to metastatic outgrowth	42
The BCL-2–tumor microenvironment axis: Mechanisms of immune suppression, resistance, and pathways to therapeutic reprogramming	42
Stereotactic body radiotherapy as an alternative to brachytherapy in cervical cancer (SCORE): A systematic review and meta-analysis	42
Bidirectional role of neutrophils in lung cancer: Mechanisms and therapeutic implications	41
Mapping the research landscape of HPV-positive oropharyngeal cancer: a bibliometric analysis	41
Microbiome dynamics in breast cancer: Mechanisms, therapeutic impacts and research gaps	41